How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,516 results for

Vitiligo

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3501. Pseudoporphyria due to dyazide in a patient with vitiligo. (PubMed)

Pseudoporphyria due to dyazide in a patient with vitiligo. 2379016 1990 09 13 2013 11 21 0959-8138 300 6737 1990 Jun 02 BMJ (Clinical research ed.) BMJ Pseudoporphyria due to dyazide in a patient with vitiligo. 1468 Motley R J RJ Department of Dermatology, University Hospital of Wales, Cardiff. eng Case Reports Journal Article England BMJ 8900488 0959-8138 0 Antihypertensive Agents 0 Drug Combinations 0J48LPH2TH Hydrochlorothiazide 14124-50-6 hydrochlorothiazide-triamterene WS821Z52LQ

Full Text available with Trip Pro

1990 BMJ : British Medical Journal

3502. Vitiligo and disorders of the retinal pigment epithelium. (PubMed)

Vitiligo and disorders of the retinal pigment epithelium. The association of vitiligo with inflammation of the uveal tract is well established. The relationship between vitiligo and hypopigmentation and/or degeneration of the retinal pigment epithelium (RPE) not secondary to ocular inflammation has not been adequately investigated. Sixty (27%) of 223 consecutive patients with vitiligo were found to have some evidence of RPE hypopigmentation ranging from mild, focal areas of involvement in most (...) cases to extensive RPE degeneration with a retinitis pigmentosa-like syndrome in one patient. Fifteen (25%) patients complained of night blindness. Only 6 (4%) of 148 patients in a control group had similar funduscopic findings (p less than 0.001). None of these patients were symptomatic. There have been isolated reports of vitiligo occurring with tapetoretinal degeneration. We report 2 patients with both vitiligo and retinitis pigmentosa.

Full Text available with Trip Pro

1983 The British journal of ophthalmology

3503. Progressive vitiligo, mental retardation, facial dysmorphism, and urethral duplication without chromosomal breakage or immunodeficiency. (PubMed)

Progressive vitiligo, mental retardation, facial dysmorphism, and urethral duplication without chromosomal breakage or immunodeficiency. A boy, born to first cousin parents of Algerian origin, first presented at the age of 9 years with growth failure, mental retardation, and dysmorphic facies. Progressive vitiligo developed from the age of 12 and distal duplication of the urethra was later recognised. The basis of this syndrome remains to be determined; autoimmune disease, chromosomal breakage

Full Text available with Trip Pro

1992 Journal of Medical Genetics

3504. Vitiligo and photosensitivity. (PubMed)

Vitiligo and photosensitivity. 3143454 1989 01 25 2008 11 20 0959-8138 297 6656 1988 Oct 29 BMJ (Clinical research ed.) BMJ Vitiligo and photosensitivity. 1126 Ackroyd J J eng Letter England BMJ 8900488 0959-8138 AIM IM Female Humans Photosensitivity Disorders complications Vitiligo etiology 1988 10 29 1988 10 29 0 1 1988 10 29 0 0 ppublish 3143454 PMC1834867

Full Text available with Trip Pro

1988 BMJ : British Medical Journal

3505. A genetical model for vitiligo. (PubMed)

A genetical model for vitiligo. A genetical model is found to provide a good fit to family data on vitiligo. The model postulates that recessive alleles at a set of four unlinked diallelic loci are involved in the causation of the disorder. Under this multiple recessive homozygosis model, for normal X affected families ascertained through the affected parent, the expected segregation probability is .063; the estimated value is 0.53, which is not significantly different from the expected value

Full Text available with Trip Pro

1988 American Journal of Human Genetics

3506. Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo. (PubMed)

Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo. 7751099 1995 06 22 2013 11 21 0011-9059 34 3 1995 Mar International journal of dermatology Int. J. Dermatol. Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo. 203-5 Khalid M M Department of Dermatology, King Edward Medical College, Mayo Hospital, Lahore, Pakistan. Mujtaba G G Haroon T S TS eng Clinical Trial Comparative Study Journal Article Randomized Controlled (...) Trial England Int J Dermatol 0243704 0011-9059 0 Ointments ADN79D536H Clobetasol U4VJ29L7BQ Methoxsalen IM Administration, Cutaneous Atrophy Child Clobetasol administration & dosage adverse effects analogs & derivatives therapeutic use Drug Eruptions etiology Follow-Up Studies Humans Methoxsalen administration & dosage adverse effects therapeutic use Ointments PUVA Therapy methods Remission Induction Skin drug effects pathology Skin Pigmentation drug effects Sunlight Vitiligo drug therapy 1995 3 1

1995 International Journal of Dermatology Controlled trial quality: uncertain

3507. Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5',8-trimethylpsoralen, and psoralen in vitiligo. (PubMed)

Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5',8-trimethylpsoralen, and psoralen in vitiligo. In this paper, we report on 366 East Indian patients with vitiligo who were treated for 2 to 3 years with either 8-methoxypsoralen (8-MOP), 4,5',8-trimethylpsoralen (TMP), or psoralen and sunlight. These patients with amelanotic macules had 10 to 70% skin involvement of 1 to 50 years duration. Male and female patients from ages 12 to 70 years were randomly assigned to 8 treatment

1984 National Cancer Institute monograph Controlled trial quality: uncertain

3508. Evaluation of clofazimine in vitiligo. (PubMed)

Evaluation of clofazimine in vitiligo. 20 patients with vitiligo were treated with 100 mg of clofazimine daily. Half of these cases were exposed to sunlight and the remaining cases were given no sun exposure. After 3 months of therapy, repigmentation of lesions was seen in 2 cases only, 1 in each group. Sun exposure had no beneficial effect.

1981 Dermatologica Controlled trial quality: uncertain

3509. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. (PubMed)

Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. To compare the efficacy and safety of using a combination of fluticasone propionate (FP) and UV-A with that of either drug used alone in the long-term treatment of vitiligo.Prospective, randomized, controlled, left-right comparison study. Repigmentation was judged by a single dermatologist (L.N.-K.) and skin thickness (...) -A, and a combination of FP and UV-A seem to be safe for long-term treatment of vitiligo.

1999 Archives of Dermatology Controlled trial quality: uncertain

3510. Combination of PUVAsol and topical calcipotriol in vitiligo. (PubMed)

Combination of PUVAsol and topical calcipotriol in vitiligo. A large variety of therapeutic agents are being tried for the treatment of vitiligo, but psoralens continue to be mainstay of treatment although they are not uniformly effective. Recent advances in pathophysiology have established a perturbed calcium homeostasis in affected skin, and melanocytes were shown to express vitamin D3 receptors.The purpose of present study was to determine the efficacy of the combination of PUVAsol (...) of PUVA and calcipotriol is highly effective and works faster and may be used for shortening the therapy with PUVA in the treatment of vitiligo.

1998 Dermatology (Basel, Switzerland) Controlled trial quality: uncertain

3511. Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. (PubMed)

Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Vitiligo is a progressive condition involving a loss of pigmentation in the skin; it can be disfiguring and no effective treatment or cure exists. Although vitiligo's medical effects have been studied extensively, little attention has been paid to its psychological impact or to the effects of psychological state on the illness itself. To address these issues (...) , the present study examined the effect of cognitive behavioural therapy on coping with vitiligo and adaptation to the negative effects on body image, quality of life and self-esteem in adult patients. The study also examined whether any psychological gains acquired from psychological therapy would influence the progression of the condition itself. Two matched groups of vitiligo patients were compared, one of which received cognitive-behavioural therapy over a period of 8 weeks, while the other received

1999 The British journal of medical psychology Controlled trial quality: uncertain

3512. PUVA and PUVB in vitiligo--are they equally effective? (PubMed)

PUVA and PUVB in vitiligo--are they equally effective? The combination of psoralens with different types of ultraviolet (UVL) sources in the treatment of vitiligo has led to different reports of success. The purpose of this trial is to compare in a random right-left comparison study the efficacy and side effects of oral 8-MOP plus UVA (PUVA) and oral 8-MOP plus UVB (broadband, 290-320 nm P-UVB) in the treatment of vitiligo.The study included 24 cases of extensive vitiligo involving more than 30 (...) in the number of sessions needed to improve produce erythema and perifollicular pigmentation as well as a moderate response, the response on the UVA side always being earlier. Furthermore, the amount of joules needed to achieve the same response was 10 times greater on the UVA side than on the UVB side.The use of psoralen plus broadband UVB is as effective as PUVA in the treatment of vitiligo. However, the long-term side effects of psoralen plus UVB are unknown.

2001 Photodermatology, photoimmunology & photomedicine Controlled trial quality: uncertain

3513. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. (PubMed)

Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Encouraging results of previous uncontrolled trials suggest that calcipotriol may potentiate the efficacy of psoralen plus ultraviolet (UV) A (PUVA) therapy in patients with vitiligo.We performed a placebo-controlled double-blind study to investigate whether the effectiveness of PUVA treatment could be enhanced by combination with topical (...) calcipotriol in the treatment of vitiligo.Thirty-five patients with generalized vitiligo enrolled in the study. Symmetrical lesions of similar dimensions and with no spontaneous repigmentation on arms, legs or trunk were selected as reference lesions. In this randomized left-right comparison study, calcipotriol 0.05 mg g(-1) cream or placebo was applied to the reference lesions 1 h before PUVA treatment (oral 8-methoxypsoralen and conventional UVA units) twice weekly. Patients were examined at weekly

2001 The British journal of dermatology Controlled trial quality: uncertain

3514. Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). (PubMed)

Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Low catalase levels and cellular vacuolation in the epidermis of patients with vitiligo support major oxidative stress in this compartment. There is now in vivo evidence for increased epidermal hydrogen peroxide (H(2)O(2)) accumulation in this patient group by utilizing noninvasive Fourier Transform Raman spectroscopy (FT Raman). Epidermal H(2)O(2) can be removed (...) with a topical application of narrow band UVB activated pseudocatalase cream (PC-KUS). (Mn/EDTA-bicarbonate complex, patent No. EPO 58471 1 A), yielding initiation of repigmentation. Dead Sea climatotherapy is another successful treatment modality for vitiligo, but the mode of action has escaped definition so far.Epidermal hydrogen peroxide (H(2)O(2)) was assessed in vivo before and after 21 days treatment at the Dead Sea using noninvasive Fourier-Transform Raman spectroscopy. The effectiveness

2002 International journal of dermatology Controlled trial quality: uncertain

3515. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. (PubMed)

Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Narrow band UVB is succeeding psoralen and UVA irradiation as the main treatment of vitiligo vulgaris in several European countries. Vitamin B12 and folic acid deficiency in some vitiligo patients has prompted researchers to investigate the efficacy of these vitamins in the treatment of vitiligo. In the present controlled study we investigated the value of narrow (...) band UVB phototherapy in the treatment of vitiligo and the possible additive effect of vitamin B12 and folic acid. Twenty-seven patients with long-term stable vitiligo were included and randomized in a "UVB only" (UVB) or "UVB combined with vitamin B12 and folic acid" (UVB+) group. Patients were irradiated thrice weekly for one year, whilst repigmentation was carefully monitored. In 92% (25/27) of the patients up to 100% repigmentation was seen. Repigmentation was notable in lesions on the face

2002 Acta dermato-venereologica Controlled trial quality: uncertain

3516. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. (PubMed)

Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. There is currently no quantitative tool for evaluating vitiligo treatment response using parametric methods.To develop and apply a simple clinical tool, the Vitiligo Area Scoring Index (VASI), to model the response of vitiligo to narrowband UV-B (NB-UV-B) phototherapy using parametric tests.Prospective, randomized, controlled, bilateral left-right comparison (...) trial.North American tertiary care, university-affiliated phototherapy center.Patients older than 18 years with stable vitiligo involving at least 5% of their total body surface in a symmetric distribution.Treatment with NB-UV-B was given 3 times a week to half of the body on all patients for either 60 treatments or 6 months. The contralateral side served as a no-treatment control.Repigmentation was assessed using the VASI, which was based on a composite estimate of the overall area of vitiligo patches

Full Text available with Trip Pro

2004 Archives of Dermatology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>